{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:55:18Z","timestamp":1783392918030,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The last decade has shown a remarkable increase in the rates of illicit opioid use in Canada and internationally, which is associated with large increases in opioid related morbidity and mortality. While the differences between methadone and buprenorphine\/naloxone in terms of retention have been studied outside Canada, the unique location and design of this study, gives it a specific significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aims to describe the relative treatment retention rates for first episode opioid replacement treatment between methadone and buprenorphine\/naloxone for patients receiving daily witnessed dispensed medications in Nova Scotia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A longitudinal retrospective descriptive study analyzing secondary data from the Nova Scotia Prescription Monitoring Program on patients 18\u2009years of age and older who started first episode opioid agonist therapy with methadone or buprenorphine\/naloxone for opioid use disorder in Nova Scotia between 2014 and 2018. Treatment episode was defined as date of initial opioid agonist prescription until there is a gap of greater than 6\u2009days without receiving opioid agonist medication at a pharmacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One thousand eight hundred sixty-seven of whom were analyzed as they had at least 1\u2009day in treatment. There was significant treatment dropout within the first 2\u2009weeks of treatment, which did not show a significant difference between OAT medication (23.4% of buprenorphine\/naloxone; 22.2% methadone). Median duration of retention in treatment was 58\u2009days for those treated with buprenorphine\/naloxone and 101\u2009days for patients treated with methadone.<\/jats:p>\n                <jats:p>Multivariate cox proportional hazards model showed that buprenorphine\/naloxone use as compared to methadone lead to increased hazard of treatment dropout by 62% (HR\u2009=\u20091.62).<\/jats:p>\n                <jats:p>Hazard rate of treatment dropout for patients below 25\u2009years of age was calculated. (HR 1.53).<\/jats:p>\n                <jats:p>Median duration of retention in treatment for this subgroup of patients younger than age 25 was 37.5\u2009days for patients treated with buprenorphine\/naloxone and 69\u2009days for patients treated with methadone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data suggests that methadone is a numerically superior medication for opioid use disorder when the metric of treatment retention is viewed in isolation, for our population in Nova Scotia. However, the results should be interpreted carefully considering the number of limitations of this study. There are social\/accessibility, pharmacologic\/safety, and patient preference factors which are also key in decision making when prescribing opioid agonist therapy. These must all be considered when deciding on which medication to initiate for a patient beginning a new treatment episode with OAT for opioid use disorder. This study should stimulate further research into this important area in addiction medicine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04175-9","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:02:52Z","timestamp":1659171772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine\/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province"],"prefix":"10.1186","volume":"22","author":[{"given":"Joseph","family":"Sadek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"4175_CR1","first-page":"e146","volume":"105","author":"J Rehm","year":"2016","unstructured":"Rehm J, Goldman B, Fischer B, Kurdyak P, Gooch J. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later. Can J Public Heal. 2016;105:e146\u20139.","journal-title":"Can J Public Heal"},{"key":"4175_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder. Harv Rev Psychiatry. 2015;23:63\u201375.","journal-title":"Harv Rev Psychiatry"},{"key":"4175_CR3","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington. 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.744053.","DOI":"10.1176\/appi.books.9780890425596.744053"},{"key":"4175_CR4","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190:E247\u201357.","journal-title":"Can Med Assoc J"},{"key":"4175_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/NDT.S39692","volume":"10","author":"R Fraser","year":"2014","unstructured":"Fraser R, Mauger S, Gill K. Utilizing buprenorphine\/naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat. 2014;10:587.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4175_CR6","doi-asserted-by":"crossref","unstructured":"Ending old epidemics and addressing new outbreaks. Des Jarlais, D. C., Kerr, T., Carrieri, P., Feelemyer, J. & Arasteh, K. HIV infection among persons who inject drugs. Aids. 2016;30:815\u201325.","DOI":"10.1097\/QAD.0000000000001039"},{"key":"4175_CR7","doi-asserted-by":"publisher","unstructured":"Calcaterra SL, et al. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;23\u201326. https:\/\/doi.org\/10.1007\/s11606-018-4801-3.","DOI":"10.1007\/s11606-018-4801-3"},{"key":"4175_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","volume":"69","author":"ME Socias","year":"2018","unstructured":"Socias ME, et al. The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale. Contemp Clin Trials. 2018;69:21\u20137.","journal-title":"Contemp Clin Trials"},{"key":"4175_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/add.12865","volume":"110","author":"AJ Saxon","year":"2015","unstructured":"Saxon AJ, Commentary on Burns, et al. Retention in buprenorphine treatment. Addiction. 2015;110:656\u20137.","journal-title":"Addiction"},{"key":"4175_CR10","doi-asserted-by":"crossref","unstructured":"Mattick R, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence ( review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Cochrane Libr Syst Rev CD002207. 2014.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"4175_CR11","doi-asserted-by":"publisher","unstructured":"Anderson-Baron J, et al. Principles, practice, and policy vacuums: policy actor views on provincial\/territorial harm reduction policy in Canada. Int J Drug Policy. 2019;0\u20131. https:\/\/doi.org\/10.1016\/j.drugpo.2018.12.014.","DOI":"10.1016\/j.drugpo.2018.12.014"},{"key":"4175_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.24095\/hpcdp.38.9.05","volume":"38","author":"E Schleihauf","year":"2018","unstructured":"Schleihauf E, et al. At-a-glance - concurrent monitoring of opioid prescribing practices and opioid-related deaths: the context in Nova Scotia, Canada. Heal Promot Chronic Dis Prev Canada. 2018;38:334\u20138.","journal-title":"Heal Promot Chronic Dis Prev Canada"},{"key":"4175_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","volume":"104","author":"J Bell","year":"2009","unstructured":"Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193\u2013200.","journal-title":"Addiction"},{"key":"4175_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/add.12834","volume":"110","author":"L Burns","year":"2015","unstructured":"Burns L, et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales. Australia Addiction. 2015;110:646\u201355.","journal-title":"Australia Addiction"},{"key":"4175_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","volume":"15","author":"B Chan","year":"2021","unstructured":"Chan B, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2021;15:74\u201384.","journal-title":"J Addict Med"},{"key":"4175_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","volume":"176","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;176:133\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"4175_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","volume":"30","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine\/naloxone: a review of the literature. Am J Addict. 2021;30:305\u201315.","journal-title":"Am J Addict"},{"key":"4175_CR18","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.74018","volume":"192","author":"PA Randhawa","year":"2020","unstructured":"Randhawa PA, Brar R, Nolan S. Buprenorphine\u2013naloxone \u201cmicrodosing\u201d: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market. Can Med Assoc J. 2020;192:E73\u20133.","journal-title":"Can Med Assoc J"},{"key":"4175_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.cpr.2011.01.006","volume":"31","author":"SS Lee","year":"2011","unstructured":"Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit\/hyperactivity disorder (ADHD) and substance use and abuse\/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31:328\u201341.","journal-title":"Clin Psychol Rev"},{"key":"4175_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1080\/10826080500294858","volume":"40","author":"AS Kalbag","year":"2005","unstructured":"Kalbag AS, Levin FR. Adult ADHD and substance abuse: diagnostic and treatment issues. Subst Use Misuse. 2005;40:1955\u201381.","journal-title":"Subst Use Misuse"},{"key":"4175_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000353969","volume":"20","author":"\u00d8 Karlstad","year":"2014","unstructured":"Karlstad \u00d8, Furu K, Skurtveit S, Selmer R. Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res. 2014;20:59\u201365.","journal-title":"Eur Addict Res"},{"key":"4175_CR22","doi-asserted-by":"publisher","first-page":"108494","DOI":"10.1016\/j.jsat.2021.108494","volume":"132","author":"SJ Becker","year":"2021","unstructured":"Becker SJ, et al. Effectiveness of medication for opioid use disorders in transition-age youth: a systematic review. J Subst Abus Treat. 2021;132:108494.","journal-title":"J Subst Abus Treat"},{"key":"4175_CR23","doi-asserted-by":"publisher","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","volume":"138","author":"Medication-Assisted Treatment of Adolescents With Opioid Use Disorders","year":"2016","unstructured":"Medication-Assisted Treatment of Adolescents With Opioid Use Disorders. Pediatrics. 2016;138:e20161893\u20133.","journal-title":"Pediatrics"},{"key":"4175_CR24","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1542\/peds.2014-0992","volume":"134","author":"E Harstad","year":"2014","unstructured":"Harstad E, Levy S. Attention-deficit\/hyperactivity disorder and substance abuse. Pediatrics. 2014;134:e293\u2013301.","journal-title":"Pediatrics"},{"key":"4175_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12954-020-00394-z","volume":"17","author":"D Crowley","year":"2020","unstructured":"Crowley D, Delargy I. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report. Harm Reduct J. 2020;17:49.","journal-title":"Harm Reduct J"},{"key":"4175_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","volume":"41","author":"G Cochran","year":"2020","unstructured":"Cochran G, Bruneau J, Cox N, Gordon AJ. Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic. Subst Abus. 2020;41:269\u201374.","journal-title":"Subst Abus"},{"key":"4175_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13011-021-00358-x","volume":"16","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16:22.","journal-title":"Subst Abuse Treat Prev Policy"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04175-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:06:41Z","timestamp":1659172001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04175-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04175-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research Ethics approval for this work was sought and was granted by the Nova Scotia Health Authority Research Ethics Board. All methods were performed in accordance with the relevant guidelines and regulations and have been performed in accordance with the Declaration of Helsinki.The Nova Scotia Health Authority Ethics review board had waived the requirement of the informed consent for this study, File Number 1024552.Consent for publication of raw data not obtained but dataset is fully anonymous in a manner that can easily be verified by any user of the dataset. Publication of the dataset clearly and obviously presents minimal risk to confidentiality of study participants. The dataset includes no direct identifiers and fewer than three indirect identifiers. Research Ethics 17 approval for this work was sought and was granted by the Nova Scotia Health Authority Research Ethics Board File Number 1024552.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"516"}}